Ascletis Pharma Inc. (1672.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$5.39 (-3.41%) as of
Key statistics
- Market cap
- 5.66B
- Forward P/E
- -19.23
- EPS (TTM)
- -0.650
- Dividend yield
- 0.00%
- 52-week range
- 5.340 – 19.860
- Beta
- 0.43
- Revenue (TTM)
- 947k
- Profit margin
- 0.00%
- Analyst target
- HK$22.60
- Volume
- 966.00k
About Ascletis Pharma Inc.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Further, it offers ASC30, for obesity; ASC47 for muscle-preserving weight loss treatment; and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist. Ascletis Pharma Inc. was founded in 2013 and is based in Wan Chai, Hong Kong.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Wan Chai, Hong Kong
- Employees
- 217
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.